Senti Biosciences Holdings, Inc.

NasdaqCM:SNTI Stock Report

Market Cap: US$33.6m

Senti Biosciences Holdings Future Growth

Future criteria checks 2/6

Senti Biosciences Holdings is forecast to grow earnings and revenue by 8% and 73% per annum respectively while EPS is expected to grow by 29.4% per annum.

Key information

8.0%

Earnings growth rate

29.37%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate73.0%
Future return on equityn/a
Analyst coverage

Low

Last updated23 May 2026

Recent future growth updates

Recent updates

Analysis Article • Dec 28

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Sep 27

Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 22

Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform

Chardan Capital Markets has initiated Senti Biosciences (NASDAQ:SNTI) with a buy highlighting the potential of the company's gene circuit synthetic biology platform and engineered cell therapy pipeline. The firm says the platform and pipeline can "address several limitations of current cell and gene therapy modalities." Chardan has a price target of $12 (757% upside based on Thursday's close). "Senti (SNT) has developed a suite of technologies including logicgates, calibrated-release cytokines, small-molecule regulated promoters....[that] can be used independently or in concert to achieve an optimized therapeutic profile across multiple modalities including various engineered cell therapy types as well as viral vectors," Chardan analyst wrote. Senti has two candidates based on donor-derived CAR-NK cells: SENTI-202 for acute myeloid leukemia, and SENTI-301 for hepatocellular carcinoma. Both are expected to enter the clinic next year.
Seeking Alpha • Aug 16

Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M

Senti Biosciences press release (NASDAQ:SNTI): Q2 GAAP EPS of -$0.86. Revenue of $1.36M (+72.2% Y/Y). As of June 30, 2022, Senti Bio held cash and cash equivalents of $139.8M, which the company believes is sufficient to fund operations into 2024.
Analysis Article • Jun 13

Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqCM:SNTI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202810-82N/AN/A2
12/31/20270-60N/AN/A2
12/31/20260-39N/AN/A3
3/31/20260-52-37-37N/A
12/31/20250-61-44-43N/A
9/30/2025N/A-50-50-50N/A
6/30/2025N/A-61-49-48N/A
3/31/2025N/A-57-44-44N/A
12/31/2024N/A-55-41-41N/A
9/30/2024N/A-71-35-35N/A
6/30/20240-79-44-42N/A
3/31/20241-82-53-48N/A
12/31/20233-83-64-52N/A
9/30/20233-80-75-54N/A
6/30/20234-54-82-49N/A
3/31/20234-52-82-41N/A
12/31/20224-50-76-35N/A
9/30/20225-46-75-38N/A
6/30/20224-46-60-37N/A
3/31/20224-46-49-36N/A
12/31/20213-55-40-35N/A
9/30/20212-45-32-30N/A
12/31/20201-20-25-24N/A
12/31/20190-21N/A-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNTI's revenue (73% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: SNTI's revenue (73% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SNTI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 22:55
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Senti Biosciences Holdings, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Yevgeniya LivshitsChardan Capital Markets, LLC
Emily BodnarH.C. Wainwright & Co.